Duke Human Vaccine Institute
-
-
Administers Grant
-
2020 CISA 04-COVID Maternal Study
-
A Double-Blind, Randomized, Placebo-controlled, Phase 1 Dose Escalation Trial to Evaluate the Safety and Immunogenicity of an Inactivated West Nile Virus Vaccine, HydroVax-001, in Healthy Adults
-
A Magnetic Microparticle Kit for Cell Removal from Blood
-
A Master Protocol to Investigate the Safety, Tolerability and Immunogenicity of Bivalent BNT162b2 RNA-Based Vaccine Candidate(s) in Healthy Infants and Children
-
A PHASE 1, OPEN-LABEL DOSE-FINDING AND PHASE 2/3 PLACEBO-CONTROLLED, OBSERVER-BLINDED STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A SARS-COV-2 RNA VACCINE CANDIDATE AGAINST COVID-19 IN HEALTHY CHILDREN 5 TO 12 YEARS OF AGE
-
A PHASE 1/2, PLACEBO-CONTROLLED, RANDOMIZED, OBSERVER BLIND, DOSE-FINDING STUDY TO DESCRIBE THE SAFETY, TOLERABILITY, IMMUNOGENICITY, AND POTENTIAL EFFICACY OF SARS-COV-2 RNA VACCINE CANDIDATES AGAINS
-
A PHASE 3 MASTER PROTOCOL TO EVALUATE ADDITIONAL DOSE(S) OF BNT162B2 IN HEALTHY INDIVIDUALS PREVIOUSLY VACCINATED WITH BNT162B2
-
A Phase 1b, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Immunogenicity of mRNA-1653, a Combined Human Metapneumovirus (hMPV) and Parainfluenza Virus T
-
ABL UFO Project Task Order
-
Abbott CSA
-
Accelerating Antibody-Antigen Association Through Interrogation and Exploitation of Encounter Complex States
-
Acceleration of antibody production to conduct passive immunity NHP studies
-
Adaptive COVID-19 Treatment Trial (ACTT)
-
Administrative Supplement to CHAVI for GWAS Meta-Analyses
-
Administrative Supplement to the CHAVI for ALVAC NHP Study
-
Administrative supplement to CHAVI-ID to study novel vaccines based on 5' leader HIV/SIV immunogens
-
An open-label, pilot study to compare the safety and immunogenicity of an alternate dosing schedule (2-5 weeks, 2, and 4 months) for pentavalent rotavirus vaccine (RotaTeq) to the standard recommended schedule (2, 4 and 6 months).
-
An orally bioavailable broad-spectrum Hsp90 inhibitor (Hsp90i) therapy to suppress emerging Coronavirus (CoV) infections
-
Analysis of Germinal Center Responses to HIV-1 Envelope
-
Animal Models of Infectious Diseases Part A
-
Antibody and viral determinants of protection against CMV infection following gB/MF59 vaccination
-
Antibody and viral determinants of protection against CMV infection in the gB/MF59 vaccination cohort
-
Antigen recognition and activation of B-cell receptors of HIV-1 broadly neutralizing antibodies
-
Assessment of Clinical Grade Near-Native Cleavage-Independent Trimer Protein Compared to Membrane-Bound mRNA Expression Coupled with Glycan Deletion, Restoration and Heterologous Boosting
-
Automated detection of protein crystals in high-throughput crystallography experiments
-
Avioq _VioOne HIV Profile Supplement Assay Project
-
B-cell repertoire analysis in influenza vaccination and infection
-
Biomarker analysis of vaginal lavage samples
-
Broad neutralizing antibodies against HIV-1 from RV217 participants
-
CARE Duke-UNC Latency Biomarker Supplement Year 2
-
CARE Focus 1: Latency Biomarker Project
-
CARE Focus 2: Clearance of HIV Antigen-Positive Cells
-
CECI Supplement
-
CISA - 2017 TO# 07 - TDAP IIV in Pregnant Women (LEAD) Logical Follow-On - Base
-
CISA - 2017 TO# 07 - TDAP IIV in Pregnant Women (LEAD) Logical Follow-On - Option 1
-
CISA - 2017 TO# 07 - TDAP IIV in Pregnant Women (LEAD) Logical Follow-On - Option 2
-
CISA - 2017 TO# 07 - TDAP IIV in Pregnant Women (LEAD) Logical Follow-On - Option 3
-
CISA - 2017 TO# 07 - TDAP IIV in Pregnant Women (LEAD) Logical Follow-On - Option 4
-
CISA 07 Adult RCT COVID-19 Vaccination (Lead)
-
CISA 10-Pediatric COVID-19 Vaccination (Lead)
-
CISA 2017 06 - Clinical Consult - Base
-
CISA 2017 06 - Clinical Consult - Opt 1
-
CISA 2017 06 - Clinical Consult - Opt 2
-
CISA 2018-2019 - Clinical Consult - Opt 2
-
CISA 2018-2019 - Clinical Consult - Opt 2
-
CISA 2018-2019 - Clinical Consult - Base
-
CISA 2018-2019- Clinical Consult - Opt 1
-
CISA 2021-2022 - Clinical Consult - Opt 2
-
CISA 2021-2022 - Clinical Consult - Base
-
CISA 2021-2022- Clinical Consult CLIN 4002 - Optional Task 1, Option Year 4
-
CISA COVID Flu Immunogenicity
-
CISA COVID Peds Immunogenicity
-
CISA Clinical Consult TO I - Option 4
-
CISA Consult 2022 Contributing Task 1
-
CISA Consult 2022 Contributing Task 2
-
CISA Consult 2022 Contributing Task 3
-
CISA Lead Site Task 3: Simultaneous RVZ and all V4 Vaccination (Lead)
-
CISA Maternal COVID Immunogenicity
-
CISA RFTP Syncope Prevention Study (Lead) 2020-2022
-
CISA RFTP 2017-03 Syncope Prevention Study (Lead) - Base
-
CISA RFTP 2017-03 Syncope Prevention Study (Lead) - Option 1
-
CISA RFTP 2017-03 Syncope Prevention Study (Lead) - Option 2
-
CISA RTOP 2017-01 Apnea (Lead) - Base
-
CISA RTOP 2017-01 Apnea (Lead) - Option 1
-
CISA RTOP 2017-01 Apnea (Lead) - Option 2
-
CISA Shingrix 2020 Lead Site Task 2
-
CISA TO2 Prophylactic Antipyretics Revision 1-A
-
CISA TO2 Prophylactic Antipyretics Revision 3-A
-
CISA Task Order No. 3 Tdap Safety in Pregnant Women
-
CISA Task Order No. 3 Tdap Safety in Pregnant Women Infant Option Task 1-CLIN0002
-
CISA Task Order No. 3 Tdap Safety in Pregnant Women Infant Option Task 2-CLIN0003
-
CISA: 2015 CISA 02 - Contributing Site Base Task: Consultation for the LAIV and Asthma Study (Contributing)
-
CISA: 2015 CISA 02 - Contributing Site Optional Task 1: Enrollment and Data Collection for the LAIV and Asthma Study (Contributing)
-
CISA: 2015 CISA 03 - Lead Site Base Task: Maternal Tdap and IIV Study (Lead)
-
CISA: 2015 CISA 03 - Lead Site Optional Task 1 (Combined Options 1-11): Additional Subjects for Maternal Tdap and IIV Study (Lead)
-
CISA: 2015 CISA 03 - Lead Site Optional Task 1: Additional Subjects for Maternal Tdap and IIV Study (Lead)
-
CIVICS A - Option 21A
-
CIVICS A - Option 21A Equitable Adjustment
-
CIVICS A - Option 23B
-
CIVICS B Option 30 A&B
-
CIVICS B Option 32 A&B
-
CIVICS Component A - Option 3
-
CIVICS Component B: Option 8 Equitable Adjustment (Mod 12)
-
CIVICS Component C - Option 13A
-
CIVICS Component C - Option 16
-
CIVICS Component C - Option 3
-
CIVICS Component C - Option 8
-
CIVICS Component C - Option 8 B.1
-
CIVICS Component C - Option 9
-
CIVICs A - Option 10A
-
CIVICs A - Option 12A
-
CIVICs A - Option 12B
-
CIVICs A - Option 18A SAVE Aims 1, 2
-
CIVICs A - Option 18B SAVE Aim 3
-
CIVICs A - Option 18C
-
CIVICs A - Option 18D
-
CIVICs A - Option 23A
-
CIVICs A - Option 23C
-
CIVICs A - Option 23D
-
CIVICs A - Option 23E
-
CIVICs A - Option 23F
-
CIVICs A - Option 23G
-
CIVICs A - Option 23H
-
CIVICs A - Option 9A
-
CIVICs A - Option 9B
-
CIVICs B Option 23
-
CIVICs B Option 39
-
CIVICs C (75N93019C00054) Option 14
-
CIVICs Component B: Option 12
-
CIVICs Component B: Option 3
-
CIVICs Component B: Option 7
-
CIVICs Component B: Option 8
-
CIVICs Component B: Option 9
-
CIVICs Component C - Option 13A.1 Equitable Adjustment
-
CIVICs Component C -Option 13 Equitable Adj #2
-
CORonavirus VAriant Sequencing (CORVASEQ) Surveillance Network
-
COVID-19 Adaptive VAriant Immunologic Landscape Trial or COVAIL Trial
-
Center for HIV/AIDS Vaccine Immunology (CHAVI)
-
Center for HIV/AIDS Vaccine Immunology and Immunogen Discovery
-
Centralized HIV-1 Genes as Vaccines
-
Cervicovaginal microbiome, mucosal immunity, and pathogen factors that contribute to spontaneous clearance of Chlamydia trachomatis
-
Characterization BCG-Gag immunized macaques
-
Characterization of antibody subclasses and ADCC activity in RV305 extended, RV306, and RV328 clinical trial subjects
-
Chronic Fatigue Initiative Bio-Bank
-
Clinical Vaccine Safety Evaluation - Contributing Site - Task COVID - Optional Task 3
-
Collaboratory of AIDS Researchers for Eradication (CARE)
-
Comparison of High vs. Standard Dose Influenza Vaccines in Adult Solid Organ Transplant Recipients
-
Comprehensive T cell Vaccine Immune Monitoring Consortium (CTVIMC)
-
Conjugate nanoparticle platform development for HIV-1 envelope immunogens
-
Core C: Immunology
-
Core C: Monitoring Host Response
-
Core D: Human Translation and Verification
-
Coronavirus Vaccine Design
-
Creation of a bnAbnectin
-
Critical domains for HIV-1 entry through atypical coreceptor usage
-
Cytokine monitoring for Macrogenics trial CP-MGD014-01, Part 2
-
Cytokine monitoring for Macrogenics trial CP-MGD020-01, Parts 1A, 1B, 2
-
Defining and Redirecting Influenza Immunity After Imprinting
-
Defining parameters to induce breadth in knockin mice expressing HIV bnAb precursors
-
Defining parameters to induce breadth in knockin mice expressing HIV bnAb precursors
-
Design and Development of a Pan-betacoronavirus Vaccine
-
Development of a nonhuman primate model of fetal Zika virus infection and disease
-
Development of broadly neutralizing antibody responses in HIV-infected children
-
Dissecting the mechanisms of HIV resistance in vivo to broadly neutralizing antibodies
-
Duke Center for HIV Structural Biology
-
Duke Clinical Good Manufacturing Practices Facility for HIV/AIDS Vaccine Production
-
Duke DARPA Pandemic Prevention Platform (P3)
-
Duke Infectious Disease Response Training Consortium (DIDRT)
-
EHR Surveillance of Lower Respiratory Tract (LRTI) and Respiratory Syncytial Virus (RSV) LRTI in Infants
-
EQAPOL - 2016 to 2017 - Option 6 - BASE
-
EQAPOL - 2016 to 2017 - Option 6 - FLOW
-
EQAPOL - 2016 to 2017 - Option 6 - VIRUS
-
EQAPOL - Option 48 - 2016 to 2017 - A3R5
-
EQAPOL - Option 48 - 2016 to 2017 - LUMINEX
-
EQAPOL - Option 6 - 2016 to 2017 - ELISPOT
-
EQAPOL - Years 2017 to 2024 - BASE
-
EQAPOL ELISpot Proficiency Testing Program
-
EQAPOL LUMINEX EP Proficiency Testing Program
-
EQAPOL Option 47
-
EQAPOL Option 5
-
EQAPOL SARS CoV-2 EQA Option 42
-
EQAPOL SARS CoV-2 EQA Option 43
-
EQAPOL SARS CoV-2 Option 44
-
EQAPOL SARS CoV-2 Option 45
-
Early Infection Response
-
Early Life Vaccination to Prevent HIV acquisition during Adolescence
-
Early life B cell responses and inflammation following SARS-CoV-2 infection
-
Efficacy of immunization with 4C-MenB in preventing experimental urethral infection with Neisseria gonorrhoeae
-
Eliciting VRC01-like bNAbs by Specifically Designed Env Immunogens
-
Emerging Infectious Diseases - Coordination Center
-
Enhancing protective antibody responses for a GM-CSF adjuvanted HIV vaccine
-
Epigenetic Control of the CD8+ T-cell Response to HIV
-
Experimental Human Infection with Isogenic Mutants of Neisseria gonorrhoeae
-
External Quality Assurance Program Oversight Laboratory
-
Focus 1: Detection of HIV Antigen-Positive Cells
-
Genomic epidemiology of Treponema pallidum strains infecting women and men in low-income countries to inform syphilis vaccine development (INV-036560)
-
Gonorrhea Vaccine Cooperative Research Center (GV-CRC); Core C: Host Response Monitoring
-
HIV Envelope-specific functional antibody responses in HIV-exposed, HIV-vaccinated infants
-
HIV Research for Prevention 2018: Vaccine, Microbicide and ARV-based Prevention Science (HIVR4P)
-
HIV-1 vaccine-elicited antibodies target envelope glycans
-
HIVRAD Project 1: Age-related impact on early life B cell lineage-designed SOSIP HIV Env vaccination
-
HVTN 3002 Protocol Funding (PF) - Durham Protocol-Specific Site
-
HVTN Phase 1 Protocol Funding
-
Harnessing Antibody-Mucus Interaction to Prevent HIV Transmission
-
Harriet Robinson GeoVax B63521 PPF
-
High throughput platform to engineer light-controlled inhibitors against Guanine Exchange Factors of the Dbl Family
-
Humoral and cellular immunity during acute HIV-1
-
Humoral immune correlates of protection against congenital CMV and HSV transmission in HIV-infected women
-
Hyperimmune globulin treatment of Zika virus during pregnancy to reduce Congenital Zika Syndrome
-
IMPAACT 2021 Core funding PTCL 11
-
IMPAACT PTCL 17 Trial
-
IMPAACT Trial--13 CF
-
IMPAACT trial
-
IQA Option 18 - UK NEQAS Proficiency Testing Cryo
-
IQA Option 25 -PBMC Cryopreservation Proficiency Testing
-
IQA Option 4
-
Identifying key determinants of IgG transplacental transfer from HIV-infected mothers to their fetus
-
Identifying key determinants that modulate maternal IgG transplacental transfer to the fetus
-
Identifying maternal immune correlates of protection against perinatal mother-to-child transmission (MTCT) in a large cohort of clade C HIV infected women
-
Immunogen Design Strategies To Direct Hiv-1 Broadly Neutralizing Antibody Maturation By Probability-Based Targeting Of Critical Mutations
-
Immunogen Design for Induction of HIV distal gp41 broadly neutralizing antibodies
-
Immunogen Design of HIV Sequential Envelopes Derived from SHIV-infected Macaques
-
Immunogenicity and Efficacy of SARS-CoV-2 stabilized prefusion Spike protein vaccines in infant rhesus macaques-Supplement
-
Immunologic and virologic determinants of congenital Cytomegalovirus transmission and disease in rhesus monkeys
-
Immunologic and virologic determinants of congenital Cytomegalovirus transmission and disease in rhesus monkeys-Diversity suppl
-
Immunological Correlates of Syphilis Protection
-
Immunology Quality Assesment Program Option 1
-
Immunology Quality Assesment Program Option 2
-
Immunology Quality Assesment Program Options 1-6
-
Immunology Quality Assessment Program - Option 41
-
Immunology Quality Assessment Program Option 3
-
Immunology Quality Assessment Program Year 5
-
Immunology Quality Assessment Program Year 7
-
Indexus Contract
-
Induction of protective antibodies for HIV vaccine development
-
Infant immune correlates of perinatal mother to child transmission of HIV
-
Innate antiviral factors in breast milk and the oral HIV-1 reservoir
-
International Maternal Pediatric Adolescent AIDS Clinical Trial (IMPAACT) Group
-
Isolation of protective ZIKV-neutralizing maternal monoclonal antibodies for safe prophylactic use in the preconception period
-
LOC-IMPAACT Leadership Group
-
Langorin-eOD project
-
Lead Site Optional Task 1: Babies COVID-19 Vaccination
-
Lead Site Task 1: Simultaneous RZV and all V4 Vaccination (Lead)
-
Lead Site Task 4: Simultaneous RZV and all V4 Vaccination (Lead)
-
Lead Site Task 5: Simultaneous RZV and all V4 Vaccination (Lead)
-
Lead Site Task 6: Simultaneous RZV and all V4 Vaccination (Lead)
-
Long-term effects of total body irradiation on measles-induced immunological memory
-
MASTER PHASE 1/2/3 PROTOCOL TO INVESTIGATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF BIVALENT BNT162b2 RNA-BASED VACCINE CANDIDATE IN HEALTHY CHILDREN
-
METHODS TO TEST LIFESTYLE, VAGINAL MICROENVIRONMENT, AND GENITOURINARY SYMPTOMS ACROSS MENOPAUSE TRANSITION
-
Macrogenics Cytokine Profiling Subcontract
-
Maternal immune protection against congenital CMV infection
-
McElrath Objective 3-Evaluate potential mucosal quality indicators
-
McElrath Objective 3-Evaluate potential mucosal quality indicators
-
Mechanisms controlling induction of HIV V1V2 glycan broadly neutralizing antibodies
-
Messenger RNA Immunogens for initiation of protective HIV non-neutralizing antibodies
-
Messenger RNA immunogens for initiation of HIV V3-glycan neutralizing B cell lineages
-
Methods to Test the Role of Age-related Lifestyle and Vaginal Microenvironment Changes and the Prevention, Treatment, and Progression of Genitourinary Syndrome of Menopause
-
Molecular signatures of broad neutralization in HIV infected children
-
Mucosal antibody protection against postnatal SIV transmission in natural hosts of SIV
-
NIAID Virology Quality Assurance - Options 27 Only
-
NIAID Virology Quality Assurance - Year 3 Option 28
-
NIAID Virology Quality Assurance - Year 4 Option 3
-
NSF Grad Res Fellowship Prog Perley
-
Natural killer cell regulation of the germinal center HIV neutralizing antibody response
-
Natural killer cell regulation of the germinal center HIV neutralizing antibody response
-
Neonatal Immunity to novel TF SHIVs
-
Neutralizing and non-neutralizing antibody effector functions in HIV infected children
-
Neutralizing antibody vaccine for pandemic and pre-emergent coronaviruses - Base
-
Non-human Primate Binding Antibody Evaluation
-
Nonhuman Primate Core Virology Laboratory for AIDS Vaccine Research and Development - Base
-
Nonhuman Primate Core Virology Laboratory for AIDS Vaccine Research and Development - Option 11 Year 5
-
Nonhuman Primate Core Virology Laboratory for AIDS Vaccine Research and Development - Option 15
-
Nonhuman Primate Core Virology Laboratory for AIDS Vaccine Research and Development - Option 4 Year 5
-
Novel Immunogens to Elicit Broadly Cross-reactive Antibodies That Target the Hemagglutinin Head Trimer Interface
-
Novel nanoparticle platform for antiviral vaccine and therapeutics
-
Novel vaccine strategies to induce V2 apex-directed broad neutralizing antibodies
-
OPP 1114721 - Supplement to RV144
-
Option Three (3) of Contract No. 200-2012-53663, Task Order 0001
-
P186 Research Analysis
-
Permar IMPAACT 2004 stability study QAU
-
Phase I therapeutic testing of viral-vectored vaccines that shift CD8+ T cell immunodominance to conserved regions of HIV-1- The CM Study
-
Pilot studies to translate human diagnostics in NHP models
-
Pre-infection B cell repertoire primed by the gut commensal bacteria enhances post-infection SIV envelope gp120-specific antibody response in African green monkey
-
Preclinical and Translational Vaccine Development Support for HIV and Other Candidate Agents - Task A
-
Production of HIV-1 Envs #2
-
Production of cGMP 16055 NFL Trimer
-
Project 1: Immune correlates of cCMV
-
Project 2: Impact of immune-based intervention on viral rebound in orally SHIV infected infant monkeys
-
Project 2: RNA vaccination in early life to induce potent and broad HIV Env-specific antibody responses
-
Project 2: The origin, predictors, and immune correlates of viral rebound in orally SHIV infected infant monkeys
-
Protein Production Facility
-
Protein Production Facility
-
Proteomics-Driven Reverse Vaccinology for Gonorrhea
-
QBI - reagent support quote
-
RERF year 7 funding
-
RFTP 2016 CISA 01 - Base - FLUAD vs. Fluzone® High-Dose Study (Lead)
-
RFTP 2016 CISA 03 - Base - Fever after simultaneous vaccination (Lead)
-
RFTP 2016 CISA 03 - Option 1 - Fever after Simultaneous Vaccination (Lead)
-
RFTP 2018 CISA 05 FLUAD Logical Follow On Task 1
-
RTOP 2018 CISA 01 Flublok Lead Base
-
RTOP 2018 CISA 01 Flublok Lead Task 1
-
RTOP 2018 CISA 01 Flublok Lead Task 2
-
RTOP 2018 CISA 01 Flublok Lead Task 3
-
RTOP 2018 CISA 01 Flublok Lead Task 4
-
Radiation Survival Cohort - Immune Monitoring Core
-
Rapid Differential Diagnosis of COVID-19 and Common Respiratory Infections
-
Rapid, Near Patient Nucleic Acid Testing for Infant Cytomegalovirus (CMV) Infection
-
Reducing disparities in adolescent HPV vaccination coverage in the Carolinas
-
Regional Biocontainment Laboratories Facility and Building System Upgrades Support
-
Role and Mitigation of Inflammasomes and Inflammation During COVID-19
-
Role of neutralizing antibodies in HIV-1-infected and vaccinated mothers in MTCT
-
SHIV/HIV Env-antibody coevolution as a molecular guide to V3 glycan targeted vaccine design
-
SIV-specific immunity in breast milk during infection and after vaccination
-
SOSIP-NP/mRNA combination for novel preventive and therapeutic HIV-1 vaccine regimens
-
SRA - 360BioLabs External Proficiency Assessment of Flow Intracellular Cytokine Staining (ICS) Assays
-
SRA - Crux BioLabs External Proficiency Assessment of Flow Intracellular Cytokine Staining (ICS) Assays
-
SRA - EQAPOL Luminex Program - CSL Limited
-
SRA - EQAPOL Luminex Program - Peter MacCallum Cancer Centre
-
SRA Core Service - SARS-CoV2 Clinical Endpoint Assay Protocol
-
SRA Core Services - Crux BioLabs ELISpot Testing
-
SRA Core Services - EP LAg Testing
-
SRA Core Services - SIV Mid Testing
-
Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine when Administered Concomitantly with Routine Pediatric Vaccines in Healthy Toddlers and Infants
-
Seraworx - EQAPOL ELISPOT SRA
-
Simple interventions to Improve Rotavirus Vaccine Effectiveness (SIRVE)
-
Statistical methods for HIV-1 immune correlates studies
-
Strategies to Target CMV Glycoprotein B Antigenic Domain-2 by B Cell Lineage Maps
-
Structural and biophysical studies on natural SARS-CoV-2 variants
-
Structural characterization of Fab-dimerized glycan-reactive antibodies that neutralize HIV-1
-
Structure, dynamics and evolution of the HIV-1 Phe-43 cavity
-
Structure-function Analysis of Infection and Vaccine Induced B-Cell Reoertiures-Supplement
-
Structures of initial CD4 engagement with pre-fusion, closed HIV-1 Envelope trimer and early CD4-induced conformational changes required for infection
-
Studying the effect on HIV-1 Env structure and immune response to HIV-1 infection in mucosal fluids using Negative Stain Electron Microscopy
-
Subcontract from Pax Vax for production of 4 505 gp140 proteins
-
Subcontract from UAB for Tetramer Production
-
Synthesis of V3 scaffolds
-
T Cell and Monocyte Telomere Length Dynamics in Patients with COVID-19
-
Targeting natural killer cells to enhance HIV vaccine responses
-
Task Area B-D Task Order 16-0058.B1C1D1.0076
-
Testing the ability of antibody-mucin interactions to provide vaccine function
-
The B cell repertoire and antibody maturation elicited by adjuvanted HIV envelope vaccines in infants
-
The duality of vaccine elicited HIV specific-IgA antibodies: Providing protection or diminishing protection
-
The origin, predictors, and immune correlates of viral rebound in orally SHIV infected infant monkeys
-
The relationship between maternal ZIKV-specific and ADE antibodies and fetal outcome
-
Transmission-blocking potential of novel HIV Env-specific mucosal antibodies
-
US Platform to Measure Effectiveness of Seasonal Influenza, COVID-19 and other Respiratory Virus Vaccines for the Prevention of Acute Illness in Ambulatory Settings
-
Universal Ebola Vaccine Antigen Design and Testing in a Mouse Model
-
VACCINE AND TREATMENT EVALUATION UNITS (VTEU) PROTOCOL DEVELOPMENT, IMPLEMENTATION AND ASSAYS TASK AREA B-D PHASE 1 PK TRIAL TO EVALUATE FOSFOMYCIN TASK ORDER 16-0058.B1C1D1.0076
-
VTEU 12-0016: Task Area C: Protocol implementation
-
VTEU 12-0021 - Task C Option 1
-
VTEU 12-0021 Task C - Base
-
VTEU 13-0053 FY 2020 Option 1-Protocol Implementation
-
VTEU 13-0053 Task Area B: Phase I, single dose, open-label, parallel group study comparing the pharmacokinetics and safety of PA-824 in subjects with mild, moderate, and severe hepatic impairment to matched, normal, healthy subjects.
-
VTEU 14-0053 Task Area A Project Logistics and Site Activation
-
VTEU 14-0053 Task C Option 2 Protocol Implementation
-
VTEU 14-0053 Task C Option 3 Protocol Implementation
-
VTEU 14-0053 Task C Option 4 Protocol Implementation
-
VTEU 18-0010.B1C1.0120_Task B Base
-
VTEU 18-0010.B1C1.0120_Task C Option 1
-
VTEU FY.2018.A1B1C1D1.0077 - Task A - Option 1
-
VTEU FY.2018.A1B1C1D1.0077 Task Area A - Base
-
VTEU HHSN272201300017I/75N93019F00132-FY2020.A1B1C1D1.0123 Task Order #17 16-0076 Task C Option 3 & Task D Option 6 Extension
-
VTEU Protocol Implementation Option 1
-
VTEU RTOP 16-0027.C1D1.0079 - Task Area C Base
-
VTEU RTOP 16-0027.C1D1.0079 - Task Area D-Option 3
-
VTEU RTOP FY.2017.B8C12.0080 - Task B
-
VTEU RTOP FY.2017.B8C12.0080 - Task C - Option 1
-
VTEU RTOP FY.2017.B8C12.0080 - Task C - Option 3
-
VTEU RTOP FY.2017.B8C12.0080 - Task C - Option 8
-
VTEU RTOP FY.2019.A1B1C1D1.0103 - Task A - Base
-
VTEU Sample Task Orders
-
VTEU TO #132 Base - Task Area A - FY.2020.A1B1C1D1.0123 - Option 2.A
-
VTEU Task A Base - FY.2017.A1B1C1D1.0048
-
VTEU Task A Option 1 - FY.2017.A1B1C1D1.0048
-
VTEU Task A Protocol FY.2015.A4D14.0033
-
VTEU Task Area A - FY.2015.A1.0016 Base
-
VTEU Task Area A - FY.2020.A1B1C1D1.0123 - Base
-
VTEU Task Area A - FY.2020.A1B1C1D1.0123 - Base-A
-
VTEU Task Area A - FY.2020.A1B1C1D1.0123 - Option 1
-
VTEU Task Area A, Base Protocol FY.2016.A1.0026
-
VTEU Task Area B Option 2 Protocol FY.2016.B1.0026
-
VTEU Task Area B Option 2 Protocol FY.2016.B1.0026
-
VTEU Task Area B Protocol 15-0020.B1C1.0040
-
VTEU Task Area C Option 1 Protocol 15-0020.B1C1.0040
-
VTEU Task Area C Option 2-1 Protocol 15-0020.B1C1.0040
-
VTEU Task Area C Option 2-2 Protocol 15-0020.B1C1.0040
-
VTEU Task Area C Option 2-3 Protocol 15-0020.B1C1.0040
-
VTEU Task Area C Option 3 Protocol FY.2016.C1.0026
-
VTEU Task Area C Option 3B Protocol FY.2016.C1.0026
-
VTEU Task Area D Option 8 Protocol FY.2016.D1.0026
-
VTEU Task Area D Option 8B Protocol FY.2016.D1.0026
-
VTEU Task Area D Option 9 Protocol FY.2016.D1.0026
-
VTEU Task B - FY.2017.B2C2D2.0053
-
VTEU Task B Base Protocol 14-0079.B1C1.0028
-
VTEU Task B Base Protocol 15-0066.B1C1D1.0041
-
VTEU Task B Option 2 - FY.2017.A1B1C1D1.0048
-
VTEU Task C Base Protocol 14-0024.C1D1.0037
-
VTEU Task C Option 1 - FY.2017.B2C2D2.0053
-
VTEU Task C Option 1 Protocol 14-0024.C1D1.0037
-
VTEU Task C Option 1 Protocol 14-0079.B1C1.0028
-
VTEU Task C Option 1 Protocol 15-0066.B1C1D1.0041
-
VTEU Task C Option 2 - FY.2017.B2C2D2.0053
-
VTEU Task C Option 2 Protocol 14-0079.B1C1.0028
-
VTEU Task C Option 3 - FY.2017.B2C2D2.0053
-
VTEU Task C Option 4 - FY.2017.B2C2D2.0053
-
VTEU Task D Option 1 Protocol FY.2015.A4D14.0033
-
VTEU Task D Option 2 Protocol 14-0024.C1D1.0037
-
VTEU Task D Option 2 Protocol FY.2015.A4D14.0033
-
VTEU Task D Option 3 Protocol 14-0024.C1D1.0037
-
VTEU Task D Option 3 Protocol FY.2015.A4D14.0033
-
VTEU Task D Option 4 Protocol 14-0024.C1D1.0037
-
VTEU Task D Option 4 Protocol FY.2015.A4D14.0033
-
VTEU Task D Option 5 - FY.2017.B2C2D2.0053
-
VTEU Task D Option 5 Protocol 14-0024.C1D1.0037
-
VTEU Task D Option 6 - FY.2017.B2C2D2.0053
-
VTEU Task D Protocol FY.2015.D1B1C1.0032
-
VTEU Task Order 13-0045.C1D1.0062 - Task C Option 1
-
VTEU Task Order 13-0045.C1D1.0062 - Task D
-
VTEU Task Order 16-0047 -Task C Option 1
-
VTEU Task Order 16-0047.C1.0090
-
VTEU Task Order 16-0058.B1C1D1.0076 - Task D
-
VTEU Task Order 18-0011.B1.C1.0116-Task B Base
-
VTEU Task Order 22 16-0058 - Cost to Complete
-
VTEU: Base -Task Area A: Project Logistics and Site Activation Protocol #14-0053
-
VTEU: Option 1-Task Area B: Protocol Development Protocol #14-0053
-
VTEU: Task Area C: Protocol Implementation - Option 2 Protocol #14-0053
-
VTEU: Task Area D: Research Laboratory Analysis Protocol #14-0053
-
Vaccine and Treatment Evaluation Units (VTEU)
-
Validation of the ADAMANT Platform
-
Virology Core
-
Whole genome sequencing of 100 high risk, uninfected individuals
-
Whole genome sequencing of rhesus macaques
-
Yellow Fever Vaccine Trial - U44 Clinical Trial with Najit
-
Zika virus pathophysiology during pregnancy
-
cGMP Manufacturing of an HIV-1 Env Nanoparticle